The "Right to Try" law in the United States allows terminally ill patients to access investigational drugs that have not yet been approved by the U.S. Food and Drug Administration (FDA) for general use. This law was signed into federal law on May 30, 2018, under the Trump administration. The intent behind the law is to give patients with life-threatening diseases a way to access potential treatments where no approved alternatives exist, and when they have exhausted all other available options.
Here are some key points about the Right to Try law:
1. **Eligibility**: To be eligible for treatments under the Right to Try law, a patient must have been diagnosed with a life-threatening disease or condition, must have exhausted approved treatment options, and must be unable to participate in a clinical trial involving the investigational drug. The patient's physician should recommend the experimental treatment as a suitable option.
2. **Drug Requirements**: The investigational drug must have completed Phase 1 of the FDA's approval process. Phase 1 involves tests for safety, dosage ranges, and side effects, typically in a small number of healthy volunteers or patients. The drug must still be under ongoing clinical trials intended to establish safety and effectiveness.
3. **Manufacturer Participation**: Participation by drug manufacturers is voluntary. They are not obligated to provide access to their investigational drugs under this law. Manufacturers may also charge patients for the cost of the drug, although they cannot claim the costs against insurance.
4. **FDA Role**: The FDA is somewhat bypassed under the Right to Try law, meaning that the agency's approval is not required for a patient to access an investigational drug. However, manufacturers are required to report any use of their drug under this law to the FDA, including any adverse effects.
5. **Liability and Risks**: There are risks involved for patients using drugs that have not fully passed FDA approval processes, as these drugs may not yet have proven safe or effective. Moreover, the law includes certain protections for manufacturers, sponsors, prescribers, or dispensers from liabilities, except in cases of misconduct or negligence.
6. **Criticism and Support**: The law has faced criticism and support from various quarters. Supporters argue that it provides a last resort hope for patients who have no other options, while critics caution that it might expose patients to unsafe and ineffective treatments. There is also concern that it could undermine the clinical trial process, which is essential for the thorough evaluation of new treatments.
Overall, the Right to Try law represents a significant shift in how access to experimental treatments is regulated, aiming to increase the autonomy of terminally ill patients in making treatment decisions.
Here are some key points about the Right to Try law:
1. **Eligibility**: To be eligible for treatments under the Right to Try law, a patient must have been diagnosed with a life-threatening disease or condition, must have exhausted approved treatment options, and must be unable to participate in a clinical trial involving the investigational drug. The patient's physician should recommend the experimental treatment as a suitable option.
2. **Drug Requirements**: The investigational drug must have completed Phase 1 of the FDA's approval process. Phase 1 involves tests for safety, dosage ranges, and side effects, typically in a small number of healthy volunteers or patients. The drug must still be under ongoing clinical trials intended to establish safety and effectiveness.
3. **Manufacturer Participation**: Participation by drug manufacturers is voluntary. They are not obligated to provide access to their investigational drugs under this law. Manufacturers may also charge patients for the cost of the drug, although they cannot claim the costs against insurance.
4. **FDA Role**: The FDA is somewhat bypassed under the Right to Try law, meaning that the agency's approval is not required for a patient to access an investigational drug. However, manufacturers are required to report any use of their drug under this law to the FDA, including any adverse effects.
5. **Liability and Risks**: There are risks involved for patients using drugs that have not fully passed FDA approval processes, as these drugs may not yet have proven safe or effective. Moreover, the law includes certain protections for manufacturers, sponsors, prescribers, or dispensers from liabilities, except in cases of misconduct or negligence.
6. **Criticism and Support**: The law has faced criticism and support from various quarters. Supporters argue that it provides a last resort hope for patients who have no other options, while critics caution that it might expose patients to unsafe and ineffective treatments. There is also concern that it could undermine the clinical trial process, which is essential for the thorough evaluation of new treatments.
Overall, the Right to Try law represents a significant shift in how access to experimental treatments is regulated, aiming to increase the autonomy of terminally ill patients in making treatment decisions.
5
